Back to top

Image: Bigstock

Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 9.8%

Read MoreHide Full Article

Aurinia Pharmaceuticals Inc. (AUPH - Free Report) was a big mover last session, as the company saw its shares rise nearly 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 40.9% in the past one-month time frame.

The company has seen two negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Aurinia Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Aurinia Pharmaceuticals Inc Price

Investors interested in the Medical – Drugs industry may consider Jazz Pharmaceuticals plc (JAZZ - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is AUPH going up? Or down? Predict to see what others think: Up or Down

Free: Zacks’ Single Best Stock Set to Double

Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

See 5 Stocks Set to Double>>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Jazz Pharmaceuticals PLC (JAZZ) - free report >>

Aurinia Pharmaceuticals Inc (AUPH) - free report >>